Phase I clinical studies has been completed by Glenmark Pharmaceuticals for their novel monoclonal antibody 'GBR 830' for treating autoimmune diseases.
While phase I trials took place in the Netherlands, the company said it will initiate the phase II studies for the anitbody in the US and Europe. "Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd announced today that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing," Glenmark Pharmaceuticals said.
Preparations for initiating Phase II studies in both atopic dermatitis and celiac disease in the US and Europe are well advanced, the company expects studies to commence in the next few months, it added in a statement.
Glenmark Pharma Chairman & MD Glenn Saldanha said: "We are excited about the progress of GBR 830, the first OX40 antagonist globally to successfully complete Phase 1 studies."
OX40 is a very well validated target with the potential to treat a wide array of autoimmune diseases, he added.